New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

References

• SaintignyPBurgerJARecent advances in non-small cell lung cancer biology and clinical managementDiscov Med2012137128729722541616
   PubMed Web of Science ®Google Scholar
• ChanBAHughesBGTargeted therapy for non-small cell lung cancer: current standards and the promise of the futureTransl Lung Cancer Res201541365425806345
   PubMed Web of Science ®Google Scholar
• RussoAFranchinaTRicciardiGRA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectivesOncotarget2015629268142682526308162
   PubMedGoogle Scholar
• WangSCangSLiuDThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerJ Hematol Oncol201693427071706
   PubMed Web of Science ®Google Scholar
• StinchcombeTEUnmet needs in squamous cell carcinoma of the lung: potential role for immunotherapyMed Oncol201431596024748366
   PubMed Web of Science ®Google Scholar
• DrilonARekhtmanNLadanyiMPaikPSquamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapyLancet Oncol20121310e418e42623026827
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive genomic characterization of squamous cell lung cancersNature2012489741751952522960745
   PubMed Web of Science ®Google Scholar
• LiamCKLeowHRPangYKEGFR mutation testing for squamous cell lung carcinomaJ Thorac Oncol2013812e114
   PubMedGoogle Scholar
• ZhangQZhuLZhangJEpidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patientsBMC Cancer2015158825886585
   PubMed Web of Science ®Google Scholar
• ScagliottiGVNovelloSRapettiSPapottiMCurrent state-of-the-art therapy for advanced squamous cell lung cancerAm Soc Clin Oncol Educ Book201335435823714545
   PubMedGoogle Scholar
• JohnsonDHFehrenbacherLNovotnyWFRandomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol200422112184219115169807
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• DermanBAMilehamKFBonomiPDBatusMFidlerMJTreatment of advanced squamous cell carcinoma of the lung: a reviewTransl Lung Cancer Res20154552453226629421
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• SocinskiMABondarenkoIKarasevaNAWeekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trialJ Clin Oncol201230172055206222547591
   PubMed Web of Science ®Google Scholar
• ScagliottiGHannaNFossellaFThe differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studiesOncologist200914325326319221167
   PubMed Web of Science ®Google Scholar
• CeppiPVolanteMSaviozziSSquamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthaseCancer200610771589159616955506
   PubMed Web of Science ®Google Scholar
• TakezawaKOkamotoIOkamotoWThymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancerBr J Cancer2011104101594160121487406
   PubMed Web of Science ®Google Scholar
• EttingerDSWoodDEAkerleyWNCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016J Natl Compr Canc Netw201614325526426957612
   PubMed Web of Science ®Google Scholar
• LeeYShimHSParkMSHigh EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinomaClin Cancer Res20121861760176822271877
   PubMed Web of Science ®Google Scholar
• ZugazagoitiaJPonceSPaz-AresLNecitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?Transl Lung Cancer Res201651959726958500
   PubMed Web of Science ®Google Scholar
• ThatcherNHirschFRLuftAVNecitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialLancet Oncol201516776377426045340
   PubMed Web of Science ®Google Scholar
• ReckMSocinskiMALuftAThe effect of necitumumab in combination with gemcitabine plus cisplatin on tolerability and on quality of life: results from the phase 3 SQUIRE trialJ Thorac Oncol201611680881826980471
   PubMed Web of Science ®Google Scholar
• ButtsCABodkinDMiddlemanELRandomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancerJ Clin Oncol200725365777578418089875
   PubMed Web of Science ®Google Scholar
• LynchTJPatelTDreisbachLCetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099J Clin Oncol201028691191720100966
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• RosellRRobinetGSzczesnaARandomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerAnn Oncol200819236236917947225
   PubMed Web of Science ®Google Scholar
• PujolJLPirkerRLynchTJMeta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancerLung Cancer201483221121824332319
   PubMed Web of Science ®Google Scholar
• HirschFRBoyleTAThatcherNEGFR IHC and FISH correlative analyses (SQUIRE trial): necitumumab + gemcitabine-cisplatin vs gemcitabine-cisplatin in 1st-line squamous NSCLCPoster presented at: 16th World Conference on Lung Cancer (WCLC)September 6–9, 2015Denver, CO
   Google Scholar
• HerbstPA randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC): SWOG S0819Poster presented at: 16th World Conference on Lung Cancer (WCLC)September 6–9, 2015Denver, CO
   Google Scholar
• GossGDSpaansJNEpidermal growth factor receptor inhibition in the management of squamous cell carcinoma of the lungOncologist201621220521326768483
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation trialJ Clin Oncol200725121545155217442998
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1J Clin Oncol200422577778414990632
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2J Clin Oncol200422578579414990633
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol200523255892589916043829
   PubMed Web of Science ®Google Scholar
• ClarkGMZborowskiDMSantabarbaraPSmoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21Clin Lung Cancer20067638939416800964
   PubMed Web of Science ®Google Scholar
• Wojtowicz-PragaSLeonLComparative efficacy and safety of erlotinib in non-small cell lung cancer (NSCLC) of squamous cell and adenocarcinoma histology in the phase III NCIC CTG BR.21 and Saturn (BO18192) trialsAnn Oncol201223Suppl 9ix419
   Google Scholar
• GarassinoMCMartelliOBrogginiMErlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialLancet Oncol2013141098198823883922
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• YardenYPinesGThe ERBB network: at last, cancer therapy meets systems biologyNat Rev Cancer201212855356322785351
   PubMed Web of Science ®Google Scholar
• RoskoskiRJrThe ErbB/HER family of protein-tyrosine kinases and cancerPharmacol Res201479347424269963
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• SolcaFDahlGZoephelATarget binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blockerJ Pharmacol Exp Ther2012343234235022888144
   PubMed Web of Science ®Google Scholar
• HirshVNext-generation covalent irreversible kinase inhibitors in NSCLC: focus on afatinibBioDrugs201529316718326123538
   PubMed Web of Science ®Google Scholar
• ParkKTanEHO’ByrneKAfatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialLancet Oncol201617557758927083334
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• KuanFCKuoLTChenMCOverall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysisBr J Cancer2015113101519152826461059
   PubMed Web of Science ®Google Scholar
• HeinmöllerPGrossCBeyserKHER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of HerceptinClin Cancer Res20039145238524314614004
   PubMed Web of Science ®Google Scholar
• HirschFRFranklinWAVeveRVarella-GarciaMBunnPAJrHER2/neu expression in malignant lung tumorsSemin Oncol2002291 Suppl 45158
   PubMedGoogle Scholar
• UgocsaiKMandokyLTiszlaviczLMolnarJInvestigation of HER2 overexpression in non-small cell lung cancerAnticancer Res20052543061306616080566
   PubMed Web of Science ®Google Scholar
• YiESHarclerodeDGondoMHigh C-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomasMod Pathol19971021421489127320
   PubMed Web of Science ®Google Scholar
• KanZJaiswalBSStinsonJDiverse somatic mutation patterns and pathway alterations in human cancersNature2010466730886987320668451
   PubMed Web of Science ®Google Scholar
• SoungYHLeeJWKimSYSomatic mutations of the ERBB4 kinase domain in human cancersInt J Cancer200611861426142916187281
   PubMed Web of Science ®Google Scholar
• DhanasekaranSMAlejandroBOChenGTranscriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genesNat Commun20145589325531467
   PubMed Web of Science ®Google Scholar
• SchulerMYangJCParkKAfatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialAnn Oncol201627341742326646759
   PubMed Web of Science ®Google Scholar
• MachielsJPHaddadRIFayetteJAfatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialLancet Oncol201516558359425892145
   PubMed Web of Science ®Google Scholar
• PfisterDGNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Head and Neck Cancers Version 2.2016 © 2016National Comprehensive Cancer Network, Inc Available from: NCCN.orgAccessed December 21, 2016
   Google Scholar
• SoriaJCFelipECoboMAfatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialLancet Oncol201516889790726156651
   PubMed Web of Science ®Google Scholar
• ParkKLiWZhouCPhase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomesAnn Oncol201526Suppl 9ix125ix147
   Google Scholar
• HamiltonMWolfJLRuskJEffects of smoking on the pharmacokinetics of erlotinibClin Cancer Res2006127 Pt 12166217116609030
   PubMed Web of Science ®Google Scholar
• TanakaKAkechiTOkuyamaTNishiwakiYUchitomiYImpact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancerJ Pain Symptom Manage200223541742312007759
   PubMed Web of Science ®Google Scholar
• MeloskyBChuQJuergensRLeighlNMcLeodDHirshVPointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibitionJ Clin Oncol201634141676168826884577
   PubMedGoogle Scholar
• NirschlCJDrakeCGMolecular pathways: coexpression of immune checkpoint molecules – signaling pathways and implications for cancer immunotherapyClin Cancer Res201319184917492423868869
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immuno-therapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• AsciertoMLMeleroIAsciertoPAMelanoma: from incurable beast to a curable bet – the success of immunotherapyFront Oncol2015515226217587
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• RizviNAMazieresJPlanchardDActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (Check-Mate 063): a phase 2, single-arm trialLancet Oncol201516325726525704439
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• LynchTJBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyJ Clin Oncol201230172046205422547592
   PubMed Web of Science ®Google Scholar
• ScarpaceSLMetastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapiesDrugs Context2015421228926576187
   PubMedGoogle Scholar
• CallahanMKPostowMAWolchokJDCTLA-4 and PD-1 pathway blockade: combinations in the clinicFront Oncol2014438525642417
   PubMed Web of Science ®Google Scholar
• LarkinJHodiFSWolchokJDCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731312701271
   PubMed Web of Science ®Google Scholar
• PatnaikASocinskiMAGubensMAPhase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort DJ Clin Oncol201533Suppl8011
   Google Scholar
• AntoniaSJGoldbergSBBalamanoukianASPhase IB study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLCJ Clin Oncol201533Suppl3014
   Google Scholar
• OrloffMWeightRValsecchiMESatoTImmune check point inhibitors combination in melanoma: worth the toxicity?Rev Recent Clin Trials2016112818627028970
   PubMed Web of Science ®Google Scholar
• GerberDEPaikPKDowlatiABeyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologiesAm Soc Clin Oncol Educ Book201514716225993153
   PubMedGoogle Scholar
• HallPESpicerJPopatSRationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lungFuture Oncol201518117
   Google Scholar
• DienstmannRRodonJPratAGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsAnn Oncol201425355256324265351
   PubMed Web of Science ®Google Scholar
• CarbogninLPilottoSMilellaMDifferential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancersPLoS One2015106e013014226086854
   PubMed Web of Science ®Google Scholar
• CarboneDPDingKRoderHPrognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trialJ Thorac Oncol20127111653166023059783
   PubMed Web of Science ®Google Scholar
• RizviNAHellmannMDSnyderAMutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerScience2015348623012412825765070
   PubMed Web of Science ®Google Scholar
• AsciertoPACaponeMUrbaWJThe additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatmentJ Transl Med2013115423452415
   PubMed Web of Science ®Google Scholar
• HirshVIs the evaluation of quality of life in NSCLC trials important? Are the results to be trusted?Front Oncol2014417325072024
   PubMedGoogle Scholar
• HirshVAre the data on quality of life and patient reported outcomes from clinical trials of metastatic non-small-cell lung cancer important?World J Clin Oncol201344828424926427
   PubMedGoogle Scholar
• GeaterSLXuCRZhouCSymptom and quality of life improvement in LUX-Lung 6: an open-label phase III study of afatinib versus cisplatin/gemcitabine in Asian patients with EGFR mutation-positive advanced non-small-cell lung cancerJ Thorac Oncol201510688388925933111
   PubMed Web of Science ®Google Scholar
• YangJCHirshVSchulerMSymptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273342335023816967
   PubMed Web of Science ®Google Scholar